Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to 102.85%.

  • Lineage Cell Therapeutics' EBITDA Margin fell 12400.0% to 102.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 325.27%, marking a year-over-year decrease of 645700.0%. This contributed to the annual value of 226.11% for FY2024, which is 503900.0% up from last year.
  • Lineage Cell Therapeutics' EBITDA Margin amounted to 102.85% in Q3 2025, which was down 12400.0% from 715.37% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' EBITDA Margin registered a high of 56.48% during Q4 2021, and its lowest value of 1803.07% during Q1 2021.
  • Its 5-year average for EBITDA Margin is 419.31%, with a median of 301.45% in 2021.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' EBITDA Margin surged by 16809400bps in 2022, and later crashed by -3629700bps in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' EBITDA Margin stood at 56.48% in 2021, then crashed by -514bps to 346.68% in 2022, then rose by 12bps to 304.69% in 2023, then surged by 42bps to 178.17% in 2024, then soared by 42bps to 102.85% in 2025.
  • Its EBITDA Margin was 102.85% in Q3 2025, compared to 715.37% in Q2 2025 and 433.09% in Q1 2025.